Metropolis Healthcare Q1 FY27: Volume-led growth delivers sharper margins

Metropolis Healthcare started FY27 with a strong first quarter. Consolidated revenue rose to INR 450.2 crore in Q1 FY27, up 16.6% year-on-year. Profitability improved faster than revenue. EBITDA increased to INR 113.2 crore, up 27.1%, and EBITDA margin expanded 210 basis points to 25.2%. PAT came in at INR 56.9 crore, up 25.8%, with PAT margin at 12.6%.

A key point in both the investor presentation and management commentary was the nature of this growth. Management stated there have been no price increases for about 18 months, yet the company still delivered mid-teen revenue growth. The quarter was driven largely by volumes and mix. Patient volumes rose 10% year-on-year to 3.69 million and test volumes grew 11% to 7.83 million. Realisations improved too, with revenue per patient up 6% to INR 1,219 and revenue per test up 5% to INR 575.

Channel momentum and mix are doing the heavy lifting

The business continued to grow across both channels. B2C revenue was INR 257 crore, up 18% year-on-year, while B2B revenue was INR 193 crore, up 15%. On the call, management shared that B2C patient volume growth was about 13.5%, while B2B patient volume growth was about 6%.

The company’s two strategic growth engines stayed ahead of the base business. TruHealth revenue rose to INR 81 crore, up 22% year-on-year, and contributed 18% of quarterly revenue. Specialty Diagnostics revenue reached INR 178 crore, up 17% year-on-year, and contributed 40% of revenue. Segment contribution in Q1 FY27 was disclosed as 40% Specialty, 25% Semi-Specialty, 18% TruHealth, and 17% Routine.

Management linked the quarter’s realisation improvement largely to this richer mix, rather than pricing. On TruHealth, the company highlighted premiumisation initiatives such as consultative wellness delivery, vitals checks, consult and ECG-led extensions, and dedicated Wellness Zones at marquee centres. It also referred to radiology-integrated wellness packages growing over 40% and premium TruHealth packages growing over 50%.

On Specialty, the investor presentation highlighted scientific expansion and new launches, including an oncology panel described as a 1,000-gene panel. Management emphasised that specialty success requires deep scientific capability and clinician trust, not only new equipment. The company cited quality metrics including a 99% EQAS score and 99.99% report accuracy.

Reach expansion and productivity are reinforcing each other

Metropolis continues to scale its access footprint while pruning weaker nodes. The service network stood at 5,003 points in Q1 FY27, up 8% year-on-year. Over the last five years, the company added 2,471 service points. In the quarter, it added 295 service points but rationalised 318 non-productive centres. Management clarified on the call that such pruning is not a quarterly event and is typically done once in 12 to 18 months, and that the closures did not impact revenue because these locations were low productivity.

Lab count was 209 in Q1 FY27, down from 212 in FY26. The company stated it consolidated seven labs with acquired entities during the quarter. Management also indicated that lab rationalisation had already been done where overlaps existed, and the focus is now on improving the centre-to-lab ratio mainly via centre additions. The company cited an improvement in centre-to-lab ratio to 24:1 in Q1 from 21:1 last year, with management targeting around 30:1 by year-end.

Geographic diversification in domestic revenue was highlighted with a clear split: West 50%, South 27%, North 18%, and East 6%. By city tier, Tier I accounted for 67% of domestic revenue, Tier III for 26%, and Tier II for 7%. Growth by tier showed Tier III leading at 25% year-on-year. Management discussed Tier 2 and Tier 3 expansion as structural, helped by healthcare access improving beyond metros and a broader shift from unorganised labs toward trusted chains.

Metropolis 3.0: technology, science, and disciplined growth

The company positioned its next phase under the Metropolis 3.0 strategy with four pillars: leading with technology, differentiating scientifically, consistent profitable growth, and brand promise with strong governance.

On technology, the investor presentation described a stack comprising a second-generation POS platform (Registration and Invoicing Platform 2.0), a partner portal for lifecycle management, a customer data platform for a 360-degree view and AI-led personalisation, and a CRM with CPQ to manage dynamic pricing. Management also referenced DPDP-compliant patient data handling.

On science, the company disclosed 36 new tests added in Q1 FY27 and 347 tests added in FY26. It highlighted expansion across oncology, nephrology, gynecology and infectious and chronic disease segments, with genomics and molecular testing growing. The presentation also referenced a Clinician Decision Support System patent (TB Metrobot) and a scientific advisory approach described as Next Best Action for chronic disease management.

Acquisitions remain part of the playbook, but management framed them as disciplined. In the call, management stated recent acquisitions are integrated and Core Diagnostics is in the final leg of integration. The Core acquisition was described as a build-versus-buy acceleration for genomics by 2 to 3 years, plus a lever to strengthen North India. Management stated North now contributes 18% of company revenue and has emerged as the fastest-growing region. It also reiterated a plan to lift Core Diagnostics to around 25% EBITDA margin over three to four years from acquisition, while noting Core is currently at high single-digit margin.

Guidance: steady on growth, confident on margins

Management reiterated FY27 revenue growth guidance of 14% to 15%, expected to be primarily volume-driven. It guided for 100 to 150 basis points EBITDA margin improvement in FY27 and maintained a medium-term target to reach 27% to 28% EBITDA margin over this year and the next.

On pricing, management stated it is not contemplating a price increase in the near term, although it acknowledged inflation may need to be partially passed on when market conditions allow. It also clarified that CGHS pricing revisions are not material for Metropolis because CGHS contributes about 1% of overall revenue.

Capex guidance was also specific. Management said FY26 capex was INR 65 crore and FY27 capex is expected to be similar, for the group including acquired entities.

The quarter’s theme was execution clarity. Growth was broad-based across B2C, B2B, regions, and test categories, while margin expansion suggests operating leverage is starting to show up as network utilisation improves. The key monitorables from here are whether specialty mix moves toward the stated 45% ambition, whether TruHealth premiumisation remains consistent, and how quickly Core Diagnostics margin steps up from the current high single-digit base.